# About Semaglutide Prescribed: An Independent Editorial Digest

> Semaglutide Prescribed is an independent editorial project that publishes plain-spoken, cited summaries of the peer-reviewed semaglutide research. Not a clinic, not a pharmacy, not medical advice.

An independent editorial digest of the published semaglutide literature.

## What this site is

Semaglutide Prescribed is an independent editorial project that publishes plain-spoken summaries of the peer-reviewed research literature on semaglutide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site exists because the public conversation around this medicine is loud and the primary literature is not. Our aim is narrow and useful: take what the trials actually measured — the STEP weight-management figures, the SUSTAIN-6 and SELECT cardiovascular outcomes, the FLOW kidney data, the safety reviews — and state them calmly, in plain language, with every quantitative claim traced to its source.

## What the name means

The word "prescribed" in our name is editorial framing, not a description of any service we offer. It signals our subject — a prescription medicine and the evidence behind it — and the angle we take: reading the record as it stands once a drug has reached approval and routine use. It is a position this publisher occupies relative to the literature. It is not a claim that this site prescribes anything, fills any prescription, runs a clinic, or connects readers to one. We do none of those things.

Semaglutide is an FDA-approved medicine, and we treat it as exactly that: an approved drug with a large, public evidence base worth summarizing accurately.

## How we handle the evidence

We lead with the obesity and weight-management evidence because that is this site's focus, then place it alongside the cardiovascular, kidney and liver record and the safety literature. We report doses only as they appear in published trials and approved labeling, always in the third person, and never as a recommendation for any individual. Community-reported experiences are clearly labeled anecdotal and kept separate from controlled findings. We use generic compound names only and name no brands. Where the evidence is uncertain — the unconfirmed cancer signals, the lean-mass question, the regain after stopping — we say so plainly rather than smoothing it over. If a claim is not in the published literature, it is not on this site.

---

A measured, fully cited reading of the semaglutide trial record, with the weight-management evidence read first and the open questions kept in plain sight — an editorial digest, not a clinic, a prescriber, or a vendor.